Loading...
Docoh

Luminex (LMNX)

The mission of Luminex is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. The Company offers a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. Luminex accelerates reliable answers while simplifying complexity and deliver certainty with a seamless experience.

Company profile

Ticker
LMNX
Exchange
CEO
Nachum Shamir
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Luminex International, Inc. • Luminex B.V. • Luminex 2 B.V. • Luminex 3 B.V. • Luminex Debt Holding, LLC • Nanosphere, LLC • Luminex Molecular Diagnostics, Inc. • Luminex Trading (Shanghai) Company Limited, a limited liability company • Luminex Japan Corporation Ltd. • Labpac Pty Ltd ...
IRS number
742747608

LMNX stock data

Calendar

5 May 21
26 Jun 22
31 Dec 22
Quarter (USD) Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 271.56M 271.56M 271.56M 271.56M 271.56M 271.56M
Cash burn (monthly) 12.62M (no burn) (no burn) (no burn) 7.19M (no burn)
Cash used (since last report) 187.63M n/a n/a n/a 106.9M n/a
Cash remaining 83.93M n/a n/a n/a 164.66M n/a
Runway (months of cash) 6.7 n/a n/a n/a 22.9 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
14 Jul 21 Todd C. Bennett Common Stock Sale back to company Dispose D No No 37 30,266 1.12M 0
14 Jul 21 Todd C. Bennett Common Stock Sale back to company Dispose D No No 37 17,342 641.65K 30,266
14 Jul 21 Todd C. Bennett Stock Option Common Stock Sale back to company Dispose D No No 23.09 72,976 1.69M 0
14 Jul 21 Todd C. Bennett Stock Option Common Stock Sale back to company Dispose D No No 24.43 16,191 395.55K 0
14 Jul 21 Todd C. Bennett Stock Option Common Stock Sale back to company Dispose D No No 21.98 12,849 282.42K 0
14 Jul 21 Todd C. Bennett Stock Option Common Stock Sale back to company Dispose D No No 18.04 14,652 264.32K 0
14 Jul 21 Collins Charles J. Common Stock Sale back to company Dispose D No No 37 26,550 982.35K 0
14 Jul 21 Collins Charles J. Common Stock Sale back to company Dispose D No No 37 23,244 860.03K 26,550
14 Jul 21 Collins Charles J. Stock Option Common Stock Sale back to company Dispose D No No 23.09 64,868 1.5M 0
14 Jul 21 Collins Charles J. Stock Option Common Stock Sale back to company Dispose D No No 24.43 18,888 461.43K 0
0.0% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 1 5 -80.0%
Opened positions 0 5 EXIT
Closed positions 4 0 NEW
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 304.01M EXIT
Total shares 1 126.54K -100.0%
Total puts 0 0
Total calls 0 2.7K EXIT
Total put/call ratio
Largest owners Shares Value Change
Huntington National Bank 1 $0 0.0%
Largest transactions Shares Bought/sold Change
Mirae Asset Global Investments 0 -107.41K EXIT
BNP Paribas Arbitrage 0 -11.42K EXIT
Mint Tower Capital Management B.V. 0 -7.71K EXIT
Huntington National Bank 1 0 0.0%
Parallel Advisors 0 0

Financial report summary

?
Management Discussion
  • ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
  • This Quarterly Report on Form 10-Q contains statements that are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide our current expectations of forecasts of future events. All statements other than statements of current or historical fact contained in this Quarterly Report on Form 10-Q, including statements regarding our future financial position, business strategy, impact of the reimbursement landscape, products including ARIES, VERIGENE, NxTAG, Muse, Guava, easyCyte, InCyte, Amnis, ImageStream, FlowSight and CellStream, assay sales, consumable sales patterns and bulk purchases, budgets, system sales, anticipated gross margins, liquidity, cash flows, projected costs and expenses, taxes, deferred tax assets, regulatory approvals or the impact of laws or regulations applicable to us, plans and objectives of management for future operations, and impact of prior acquisitions or future acquisitions, integration and the expected benefit of our acquisitions are all forward-looking statements. The words “anticipate,” “believe,” “continue,” “should,” “estimate,” “expect,” “intend,” “may,” “plan,” “projects,” “will” and similar expressions as they relate to us, are intended to identify forward-looking statements. These statements are based on our current plans and actual future activities, and our financial condition and results of operations may be materially different from those set forth in the forward-looking statements as a result of known or unknown risks and uncertainties, including, among other things:
  • •risks and uncertainties related to our proposed acquisition by DiaSorin S.p.A;

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: absence, agree, agreed, analyst, antitrust, asserting, attract, audit, azioni, bifurcated, billion, BNP, breach, bridge, building, cancelled, categorical, CE, certificate, Chancery, choice, Committee, confidence, constant, consummated, consummation, coupled, court, cumulative, customary, Delaware, deny, description, DGCL, Diagonal, DiaSorin, director, discourage, dissenting, district, diversion, doctrine, duty, easyCheck, Economy, endorsement, exclusive, exhibit, expiration, expired, fee, fiduciary, firm, FlowCellect, flu, forum, French, fullest, GuavaSoft, hand, home, inapplicable, INSPIRE, investor, Italy, judicial, loan, located, LumAvidin, LX, MagPlex, Mark, matter, Mediobanca, MicroPlex, Ministry, mortgage, mutually, Nexin, organized, outlook, owed, owner, Parent, proceeding, prove, purport, raw, receipt, recovery, relationship, Republic, resolution, retain, retrospective, RSV, SD, SeroMAP, Simplifying, slightly, societ, solicit, SpeedBead, sponsorship, superior, surviving, SYNCT, syncytial, syndicate, text, thereunder, timeframe, Topic, trademark, unclear, unenforceable, UniCredit, ViaCount, waiting, wholly, writing, wrote, xPONENT, XYP
Removed: absolute, accurate, accurately, achieve, acid, added, adding, addressed, adhere, advantage, affordable, aid, Alex, amplification, analyte, analyze, analyzed, animal, antibiotic, applied, approved, architecture, area, assure, attaching, automate, automation, Azar, back, bacteria, barcode, batch, began, begin, benchtop, bind, biochemical, biomarker, blood, bonding, bringing, capture, captured, care, cartridge, CDF, ceasing, cell, centered, certified, CFR, chemistry, claimed, cleared, CLIA, clinically, Clostridium, coated, collectability, collected, collecting, color, colored, combine, Commissioner, commitment, compare, competing, complex, complexity, computer, conclusion, conclusive, conducted, congregation, continuance, contrast, correcting, Cosmetic, counterparty, counting, create, credit, culture, customizable, customizing, cytometer, database, dating, declaration, deducted, delaying, demonstrate, detail, detect, detected, detection, diagnosing, difficile, digital, discovery, discretion, displayed, dissolving, distinctive, distinctly, distinguish, distraction, distribute, DNA, doubtful, dye, efficient, efficiently, effort, EMD, emitting, ensuring, enteric, enzymatic, Epidemic, established, evidence, exercise, expensed, extraction, false, family, FDCA, flexibility, flexible, fluorescence, fluorescent, footprint, foundation, functional, gain, Gen, generate, genetic, geographic, gold, GPP, halt, healthcare, highly, history, hospital, hour, hydrogen, identity, illumination, imaging, immunologic, important, independent, individual, inexpensive, infection, informed, injected, innovative, inspection, instrumentation, interested, interface, involved, IRS, isoC, isoG, issue, IVD, labeling, labor, laser, leading, Likewise, magnetic, mandatory, maximum, MDx, meaningful, medicine, menu, met, microarray, microcapillary, microscopy, microsphere, microtiter, Millipore, mixed, mixture, moderate, modular, module, multiplex, NanoGrid, nanoparticle, nasopharyngeal, natural, naturally, newly, noted, nucleic, nucleotide, occurring, operator, optimized, ordered, outbreak, outweigh, pair, particle, patient, pattern, paying, performed, performing, permit, permitting, personalized, pharmacogenetic, plate, pooled, population, posed, positive, precision, prescribe, previously, pricing, probe, processing, produce, professional, proper, prospective, protein, Protocol, purification, purpose, qualitative, reclassified, recording, regimen, relief, remeasured, remotely, reporter, represent, reputation, researcher, resistance, restatement, restating, revised, revocation, revoke, revoked, room, RP, ruling, save, scalable, scanning, scientific, Secretary, section, seek, segment, select, sensitivity, sequential, signal, signature, simple, simultaneously, single, software, solution, spatial, specificity, spectrum, speed, STAT, stored, stream, supplier, supportable, surface, suspected, suspending, swab, syndromic, synthetic, targeted, technical, temporary, terminated, tested, therapeutic, threat, today, tracking, traditional, transition, tube, type, typically, ultimate, unapproved, unavailable, Universal, utilize, versatile, viability, viewed, vitro, waived, wide, widespread, yeast